Current understanding suggests that the majority of cardiovascular events are driven by vulnerable plaques. Nonetheless, the impact of PCSK9 inhibitors on the stability of carotid plaques remains insufficiently elucidated, with a notable scarcity of relevant clinical studies. This investigation seeks to address this gap through a real-world study conducted among patients with arterial sclerosis in Asia. The primary aim is to evaluate the effects of small interfering RNA (inclisiran) on carotid plaque characteristics as assessed by ultrasound, thereby contributing valuable data to inform clinical practice.
Patients with carotid plaques as indicated by ultrasound
Men and women aged 18-75 years;
LDL-C >3.4 mmol/L without regular statin therapy or LDL-C >1.8 mmol/L after 4 weeks of statin lipid-lowering therapy.
- Known allergies or contraindications to PCSK9 inhibitors and/or statin therapy;
Prior use of PCSK9 inhibitors;
Prior history of hemorrhagic stroke;
Prior coronary artery bypass grafting or coronary intervention;
Single group
Inclisiran
DrugPatients with carotid plaques undergoing treatment with inclisiran
CIMT
Carotid artery intima media thickness
TMPT
The maximal plaque thickness
CPA
Carotid plaque area
CPV
Carotid plaque volume
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
